# IDVYNSO (doravirine-islatravir) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/doravirine-islatravir

> The PDUFA target action date for IDVYNSO (doravirine-islatravir), sponsored by Merck & Co., Inc. (MRK), is April 22, 2027. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the IDVYNSO (doravirine-islatravir) PDUFA date?

The PDUFA target action date for IDVYNSO (doravirine-islatravir), sponsored by Merck & Co., Inc. (MRK), is April 22, 2027. Status: scheduled. SEC Form 10-Q: "Idvynso is also under review in the U.S. to expand the approved indication in certain virologically suppressed adults with HIV-1 infection to include certain adults who have not previously received antiretroviral treatment; the FDA set a PDUFA date of April 22, 2027." Last confirmed November 4, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/doravirine-islatravir)

Source: SEC Form 10-Q, accession 0000310158-26-000248, https://www.sec.gov/Archives/edgar/data/310158/000031015826000248/mrk-20260930.htm (retrieved 2026-11-12). Last confirmed 2026-11-04. Cite: https://sec-api.dev/pdufa/doravirine-islatravir#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | IDVYNSO (doravirine-islatravir) |
| Codes | MK-8591A |
| Sponsor | Merck & Co., Inc. (MRK) https://sec-api.dev/companies/mrk/catalysts |
| Indications | hiv-1 infection in previously untreated adults, and in november 2025, the company |
| Modality | small_molecule |
| FDA designations | none disclosed |

## Timeline

### Nov 2025: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 3. Indication: HIV-1 infection in previously untreated adults, and in November 2025, the Company.
- First seen 2026-02-24, last confirmed 2026-02-24.
- SEC Form 10-K (accession 0000310158-26-000063): "MK-8591A is also being evaluated for the treatment of HIV-1 infection in previously untreated adults, and in November 2025, the Company announced positive topline results from the pivotal Phase 3 MK-8591A-053 trial evaluating MK-8591A in this setting." https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm

### April 20, 2026: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Idvynso | doravirine and islatravir | 4/20/2026 | To treat HIV-1 infection (as a complete regimen) in adults to replace the current antiretroviral regimen in those who are virologically-suppressed on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
- openFDA Drugs@FDA: "NDA216964 ORIG-1 (Type 1 - New Molecular Entity and Type 4 - New Combination): submission_status AP, submission_status_date 20260420, review_priority STANDARD; sponsor_name MSD; product IDVYNSO (DORAVIRINE; ISLATRAVIR)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216964%22

### April 28, 2026: PDUFA date

- Status: completed, approved. Date confidence: exact. Stage: 3.
- First seen 2025-07-29, last confirmed 2026-02-24.
- SEC Form 10-K (accession 0000310158-26-000063): "The FDA set a PDUFA, or target action, date of April 28, 2026 for the new drug application, which is based on findings of the Phase 3 MK-8591A-051 and MK-8591A-052 clinical trials." https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm
- SEC Form 10-Q (accession 0000310158-25-000059): "The FDA set a Prescription Drug User Fee Act (PDUFA), or target action, date of April 28, 2026 for the new drug application, which is based on findings of the Phase 3 MK-8591A-051 and MK-8591A-052 clinical trials." https://www.sec.gov/Archives/edgar/data/310158/000031015825000059/mrk-20250930.htm
- SEC Form 10-Q (accession 0000310158-25-000014): "The FDA set a PDUFA date of April 28, 2026 for the new drug application, which is based on findings of the Phase 3 MK-8591A-051 and MK-8591A-052 clinical trials." https://www.sec.gov/Archives/edgar/data/310158/000031015825000014/mrk-20250630.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-071380): "The FDA set a Prescription Drug User Fee Act (PDUFA) date of April 28, 2026." https://www.sec.gov/Archives/edgar/data/310158/000110465925071380/tm2521736d1_ex99-1.htm
- FDA novel drug approvals: "Idvynso | doravirine and islatravir | 4/20/2026 | To treat HIV-1 infection (as a complete regimen) in adults to replace the current antiretroviral regimen in those who are virologically-suppressed on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026

### April 22, 2027: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2026-10-29, last confirmed 2026-11-04.
- SEC Form 10-Q (accession 0000310158-26-000248): "Idvynso is also under review in the U.S. to expand the approved indication in certain virologically suppressed adults with HIV-1 infection to include certain adults who have not previously received antiretroviral treatment; the FDA set a PDUFA date of April 22, 2027." https://www.sec.gov/Archives/edgar/data/310158/000031015826000248/mrk-20260930.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-119825): "FDA set a PDUFA date for both sNDAs of April 22, 2027." https://www.sec.gov/Archives/edgar/data/310158/000110465926119825/tm2628203d1_ex99-1.htm

Calendar months: [April 2027](https://sec-api.dev/fda-calendar/2027-04)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/doravirine-islatravir.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "IDVYNSO (doravirine-islatravir) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/doravirine-islatravir

```bibtex
@misc{secapidev_pdufa_doravirine_islatravir_20261116,
  title        = {IDVYNSO (doravirine-islatravir) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/doravirine-islatravir}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_doravirine_islatravir_20261116","title":"IDVYNSO (doravirine-islatravir) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/doravirine-islatravir","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
